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Background: Human papillomavirus (HPV) infection is the main etiological factor for cervical cancer and premalignant
lesions of the cervix. The purposes of the present study were to determine the prevalence of type-specific HPV infections
and the association of different HPV types with cervical dysplasia among women in Zhejiang province, Southeast China.
Methods: A total of 15,267 women presenting to a gynaecological outpatient clinic were enrolled in this study.
Women were screened for HPV in addition to routine cervical cytology testing. Microarray hybridization and
liquid-based cytology tests were used to detect HPV genotypes and cervical cytology, respectively.
Results: Based on the population attending a gynaecological outpatient clinic, overall prevalence of any 23 HPV type
was 22.8% and multiple HPV infection was found in 4.0% of all the outpatients. HPV prevalence showed bimodal age
distribution, with a peak (55.7%) at the≤20 age group and a second one (35.5%) at >60 age group. In total samples,
the five most frequent types were HPV 16 (4.4%), 58 (2.9%), 52 (2.7%), 33 (2.2%) and 11 (1.9%). Overall HPV prevalence
increased with the severity of the cytologic result. Analysis through crude odds ratios (ORs) revealed that the cervical
lesion risk of HPV-infected women increased to about 26-fold of uninfected women (OR 26.1, 95% CI 22.4 to 30.3). The
five most risky HPV types associated with abnormal cytology were HPV 73, 16, 82, 45 and 51.
Conclusions: This study provided baseline data on HPV prevalence in women attending a gynecological outpatient
clinic in Zhejiang province. Our data will supply guidance for the primary screening and vaccination program for
cervical cancer in this area.
Keywords: Human papillomavirus (HPV), Prevalence, Genotyping, CytologyBackground
Cervical cancer is the second most common cancer
among women, with an estimated 530,000 new cases and
275,000 deaths occurring each year in the world [1,2].
There are an estimated 88% of the annual incidences
occurring in developing countries, such as China, where
approximately 75,500 new cases and 34,000 deaths
occur every year [2,3]. According to epidemiological
and molecular studies, it is well-established that human* Correspondence: Med_bp@zju.edu.cn; sunah123@126.com
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unless otherwise stated.papillomavirus (HPV) infection is the main etiological fac-
tor for cervical cancer and premalignant lesions of the cer-
vix [4,5]. So far, over 100 different HPV genotypes have
been identified, of which nearly 40 types are associated to
lesions of the female genital tract and are classified as low-
risk (LR) or high-risk (HR) based on their potential to
cause cancer [5]. There are at least 18 HR-HPV types
[6,7], of which HPV 16, 18, 31, 33, 35, 45, 52, and 58 con-
tribute to 91% of the invasive cervical cancers diagnosed
and HPV 16 and 18 account for approximately 70% of all
the case worldwide each year [8], while HPV 6, 11, 42, 43
and 44 are classified as “LR types”, which are associated
with hyperplastic lesions such as genital warts [5].
Since persistent infection of HPV is a necessary cause
of cervical cancer worldwide, DNA tests for the detec-
tion of HPV can be used as a primary screening methods is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of women with atypical or borderline cervical smears
[9,10]. In addition, the data of HPV type-specific distribu-
tion will provide guidance for the vaccination program for
cervical cancer. Prophylactic vaccines against HPV have
been developed and approved in more than 100 countries
around the world [11]. However, in China, HPV vaccines
are still under clinical trials for government approval.
There are two available HPV vaccines, a bivalent vaccine
targeted at HPV 16 and 18 and a quadrivalent HPV
vaccine targeted at HPV 6, 11, 16 and 18 [12,13]. These
current preventive HPV vaccines offer protection only
against a few HPV genotypes. HPV prevalence and sub-
type distribution varied greatly amongst different geo-
graphic areas [14,15]. Since limited cross-protection was
present between HPV types [16], knowledge of geograph-
ical differences in HPV type-specific distribution might be
very valuable for predicting the effect of current prophy-
lactic vaccines and forming the basis for the second gener-
ation vaccines targeted to specific regions.
To the best of our knowledge, limited large scale epi-
demiologic data of HPV infection have been reported in
Zhejiang Province, a coastal region in Southeast China.
In this study, we collected 15,267 samples from women
attending regular gynecological visits in Zhejiang Prov-
ince. All women were offered HPV test and ThinPrep
cytology test (TCT) to analyze the association between
HPV genotype and cervical cytology. The overall, age-
specific, genotype-specific, and state-specific prevalence
of HPV in Zhejiang province will provide guidance for




The study population consisted of 15,267 women (age, 18–
79 years; mean, 38.3 ± 7.1 years) attending a gynecological
outpatient clinic between January 2010 to December 2013
in Zhejiang Province. A woman was considered eligible to
enter the study if she a) had current or past sexual activity,
b) was not pregnant at the time of enrollment, c) had never
been screened or treated for cervical cancer, d) had not
undergone a total uterus or cervix resection, e) agreed to
undergo an HPV test and a TCT, and f) agreed to partici-
pate in the present study. This research was conducted in
accordance with the Declaration of Helsinki and a protocol
approved by the Ethics Committee of Zhejiang Medical
College (Hangzhou, China).
TCT and pathological diagnosis
Exfoliated cervical cells were collected from the orifice
of uterus and endocervical canal with a cervical brush.
The cells were washed into vials containing ThinPrep
preservative solution and were sent to the cytologylaboratory for TCT analysis. Cytological findings were
evaluated according to the Bethesda classification system
[17] and were classified as follows: a) negative; b) atyp-
ical squamous cells of undetermined significance (ASC-
US); c) low-grade squamous intraepithelial lesion (LSIL);
d) atypical squamous cells that cannot exclude HSIL
(ASC-H); e) high-grade squamous intraepithelial lesion
(HSIL).
HPV detection and genotyping
HPV DNA was extracted from the cytological rem-
nants, and was detected and genotyped using a com-
mercial HPV Genotyping Kit for 23 HPV types (Yaneng
Bioscience (Shenzhen) Co., Ltd, China), including 5 LR
types (6, 11, 42, 43 and 44), and 18 HR types (16, 18,
31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82
and 83). The kit employs DNA amplification to detect
HPV positivity and a microarray format with a nylon
membrane onto which HPV genotype-specific oligo-
nucleotide probes have been immobilized to simultan-
eously identify 23 HPV genotypes. The HPV test was
conducted according to the manufacturer’s recommen-
dation and was validated through the use of positive
and negative controls at each shift.
Statistical analysis
The data were analyzed using SPSS software for windows
(version 16.0). The prevalence of HPV according to age
and cytological lesion types was analyzed. The 95% confi-
dence intervals (CI) of HPV prevalence were based on nor-
mal approximations. Chi-square test was used to compare
the proportions between different groups, with crude odds
ratios (ORs) and 95% CI calculation to estimate the risk of
each HPV type for cervical lesions. Linear-by-linear associ-
ation test was used to investigate trend in distribution of
HPV infection according to grade of cytology abnormal-
ities. P-values were two-sided, and statistical significance
was defined as p < 0.05.
Results
Overall HPV prevalence
A total of 15,267 female out patients were enrolled in
this study, of which 3,486 cases (22.8%) were positive for
HPV infection. The prevalence of single HR-HPV was
15.8% (2408/15267) and single LR-HPV was 3.1% (474/
15267). Multiple HPV infection was found in 4.0% (604/
15267) of all the samples. Among women with multiple
infections, 82.0% (495/604) were infected with two HPV
types, 12.4% (75/604) were with three types and 5.6%
(34/604) were with more than three types. Of the HPV
positive cases, 69.1% (2408/3486) were single HR-HPV
infections, 13.6% (474/3486) were single LR-HPV infec-
tions, and 17.3% (604/3486) were infected by multi-
types, respectively.
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HPV prevalence by age group was examined in order to
assess age trends in relation to HPV infection in more
detail. Women were 18–79 years old (mean age 38.3)
and were divided into six groups according to their age.
As shown in Figure 1, the age-specific prevalence of total
HPV infection exhibited a peak of 55.7% (206/370, Pear-
son’s Chi Square test, x2 = 276.3, p < 0.001) at ≤20 years
old and a second peak 35.5% (54/152, Pearson’s Chi
Square test, x2 = 25.557, p < 0.001) at the age group >
60 years old. Similarly, the prevalence of single HR-HPV
and multiple HPV also exhibited the bimodal age distri-
bution. However, single LR-HPV infection showed rela-
tively flat curve.
HPV prevalence by type
Using the microarray method, totally 23 HPV types
were detected (18 HR types, 5 LR types). Overall, HPV
16 was the most commonly detected genotype present
with a prevalence of 4.4% (678/15267), followed by HPV
58 (2.9%, 444/15267), HPV 52 (2.7%, 414/15267), HPV
33 (2.2%, 331/15267) and HPV 11 (1.9%, 294/15267)
(Figure 2). Although HPV 11 is a LR type, its prevalence
is higher than some other HR-HPVs, such as HPV 18
and HPV 31.
HPV prevalence by cervical cytology
As shown in Table 1, the overall HPV prevalence in nor-
mal, ASC-US, LSIL and HSIL cytology samples were
16.8% (2330/13891), 80.2% (644/828), 91.2% (237/260)
and 94.4% (102/108), respectively. As expected, HPV
prevalence increased with the severity of the cytologic
result (Pearson’s Chi Square test, p < 0.001; Linear-by-
Linear association test, p < 0.001). Moreover, multiple
HPV positivity also exerted a similar increasing trendFigure 1 Age-specific prevalence of total HPV, single HR-HPV,
single LR-HPV and multiple HPV with 95% CI. Significant
differences between the peak and lowest prevalence are indicated as:
*p < 0.05; **p < 0.01.with the development of cytology abnormalities (Pearson’s
Chi Square test, p < 0.001; Linear-by-Linear association
test, p < 0.001).
In order to estimate the risk of HPV infection to have
abnormal cytology, the crude ORs for the prevalence of
HPV associated with abnormal cytology (ASC-US, LSIL,
ASC-H and HSIL) are shown in Figure 3. The overall OR
of HPV infection was 26.1 (95% CI 22.4 to 30.3). As far as
genotypes were concerned, HPV type 73 had the highest
OR, followed by HPV 16, 82, 45, and 51. The LR-HPV
type with OR > 1 was HPV 11 and 42. Additionally, the
prevalence of HR-HPV 83, LR-HPV 6, 43 and 44 in the
abnormal specimens showed no significant difference to
that in the normal specimens (Pearson’s Chi Square test,
p > 0.05) and no ORs were supplied.
Discussion
We presented a large clinic-based study (15,267 women)
of HPV prevalence in the area of Zhejiang Province,
Southeast China, from which interesting conclusions can
be drawn. HPV detection and genotyping have been sug-
gested to be incorporated in primary screening of cer-
vical lesions [18,19]. HPV typing is also very important
for characterization of the population in HPV vaccin-
ation trials and for monitoring the efficacy of HPV vac-
cines [13]. Accordingly, determination of type-specific
HPV prevalence in a region is considered to be one of
the important steps towards cervical cancer prevention.
It was observed that the overall HPV infection was
22.8% in female outpatients in this study. The overall
HPV prevalence reported from different regions of
China varied greatly, ranging from 7.2% (Chaozhou, South
China) to 36.5% (Harbin, Northeast China) [15,20]. HPV
infection in our study population was similar to that in
Fujian, Southeast China (22.5%) [21], but higher than that
in a previous population-based study in Zhejiang (13.3%)
[22]. The difference might primarily be attributed to
the fact that our work was a clinic-based study with a
much larger study cohort. In addition to geographical
differences, the observed HPV prevalence was also af-
fected by the study cohorts (clinic-based or population-
based), examination methods and time period [23].
We presented the age-related prevalence curves of
HPV infections. The prevalence of total HPV, single HR-
HPV and multiple HPV, all showed bimodal age distri-
bution, with a peak at the ≤20 age group and a second
one at the >60 age group. This has been observed in sev-
eral other studies in China [1,14,24], but differs from
most of the European countries, with a decrease in HPV
prevalence after age 20 and a levelling off after age 45
[25,26]. The actual first peak may due to the fact that
younger women are more prone to have multiple part-
ners [27] and are also less likely to have developed im-
munity to HPV [28]. The second peak of HPV infection
Figure 2 Overall prevalence of different HPV genotypes. There are 18 HR-HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82
and 83) and 5 LR-HPVs (6, 11, 42, 43, and 44).
Table 1 HPV type distribution by cytological results
HPV
type
Normal (13891) ASC-US (828) LSIL (260) ASC-H (180) HSIL (108)
N (%) N (%) N (%) N (%) N (%)
HR-HPV
16 345 (2.5) 180 (21.7) 65 (25.0) 65 (36.1) 23 (21.3)
18 154 (1.1) 89 (10.7) 18 (6.9) 9 (5.0) 3 (2.8)
31 141 (1.0) 75 (9.1) 22 (8.5) 5 (2.8) 11 (10.2)
33 190 (1.4) 63 (7.6) 26 (10.0) 25 (13.9) 27 (25.0)
35 67 (0.5) 12 (1.4) 4 (1.5) 2 (1.1) 0 (0.0)
39 140 (1.0) 34 (4.1) 5 (1.9) 4 (2.2) 1 (0.9)
45 17 (0.1) 11 (1.3) 2 (0.8) 2 (1.1) 2 (1.9)
51 42 (0.3) 19 (2.3) 13 (5.0) 4 (2.2) 5 (4.6)
52 270 (1.9) 90 (10.9) 38 (14.6) 12 (6.7) 4 (3.7)
53 87 (0.6) 10 (1.2) 5 (1.9) 3 (1.7) 0 (0.0)
56 92 (0.7) 9 (1.1) 22 (8.5) 5 (2.8) 2 (1.9)
58 264 (1.9) 93 (11.2) 32 (12.3) 12 (6.7) 43 (39.8)
59 154 (1.1) 21 (2.5) 1 (0.4) 3 (1.7) 2 (1.9)
66 70 (0.5) 29 (3.5) 9 (3.5) 6 (3.3) 1 (0.9)
68 186 (1.3) 17 (2.1) 17 (6.5) 7 (3.9) 4 (3.7)
73 8 (0.1) 4 (0.5) 7 (2.7) 4 (2.2) 1 (0.9)
82 9 (0.1) 3 (0.4) 3 (1.2) 4 (2.2) 0 (0.0)
83 15 (0.1) 3 (0.4) 0 (0.0) 1 (0.6) 0 (0.0)
LR-HPV
6 221 (1.6) 15 (1.8) 4 (1.5) 2 (1.1) 1 (0.9)
11 257 (1.9) 24 (2.9) 8 (3.1) 5 (2.8) 0 (0.0)
42 73 (0.5) 13 (1.6) 3 (1.2) 2 (1.1) 0 (0.0)
43 2 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0)
44 3 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0)
Any type 2330 (16.8) 664 (80.2) 237 (91.2) 153 (85.0) 102 (94.4)
Single 1921 (13.8) 551 (66.5) 194 (74.6) 133 (73.9) 83 (76.9)
Multiple 409 (2.9) 113 (13.6) 43 (16.5) 20 (11.1) 19 (17.6)
Negative 11561 (83.2) 164 (19.8) 23 (8.8) 27 (15.0) 6 (5.6)
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Figure 3 Risk of each HPV type for cervical lesions. Crude odds
ratios with 95% confidence intervals for the prevalence of HPV
associated with abnormal cytology (ASC-US, LSIL, ASC-H and HSIL) are
provided. Numbers on right margin are the total number of positive
specimens infected by the specified type. The prevalence of HR-HPV
83, LR-HPV 6, 43 and 44 in abnormal specimens showed no significant
difference to normal specimens (Pearson’s Chi Square test, p > 0.05)
and no ORs were provided. Reference lines for ORs of 5 and 10 are
added for readability.
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tion. The high infection rate around menopausal women
may be attributed to viral persistence or reactivation of la-
tent HPV caused by the physiologic and immunologic dys-
regulation at menopausal transition [29,30]. Accordingly,
HPV detection is clinically valuable for perimenopausal
women in cervical cancer screening program. However,
since HPV prophylactic vaccines do not have clinical bene-
fit in women infected with vaccine types at the time of vac-
cination, we assume that younger women would obtain
more benefit from “catch-up” HPV vaccination programs.
The five most common HPV types in women with
normal cytology worldwide are HPV 16, 18, 31, 58 and
52, while the rank varied by region [31]. HPV 16 and
HPV 18 are the most common oncogenic types associ-
ated with cancer, and are targeted by the vaccines [8,12].
In our population, the five most common HPV types
were HPV 16, 58, 52, 33 and 11 basing on the overall
prevalence. Similarly to most previous surveys in China
[15,24] and other population [7,32], HPV 16 was the
most common type. Somewhat differently, HPV 58 and
52 were more prevalent than the vaccine type HPV 18in our population. Moreover, no matter in normal, ASC-
US, LSIL, ASC-H or HSIL cytology samples, HPV 16, 58
and 52 were always the major type, with the rank varied.
Especially, HPV 58 was the most prevalent type in HSIL
cytology samples. Some previous studies have shown
that HPV 58 and 52 were more prevalent and overrepre-
sented in cervical cancer cases in Asia [33,34]. In China,
it was observed that the two HPV types were more
prevalent in the south and the southwest compared to
other regions among women with precancerous lesions
and cervical cancer [35-37]. The preponderance of HPV
58 and 52 in our study population is meaningful, which
enhances the hypothesis that the second-generation
HPV prophylactic vaccines including HPV 58 and 52
may offer higher protection for women in China and
other Asian areas.
As far as cytology were concerned, it was observed that
the overall HPV prevalence in normal, ASC-US, LSIL and
HSIL cytology samples were 16.8%, 80.2%, 91.2% and
94.4%, respectively. Overall HPV prevalence increased as
lesions progressed to higher grade ones, suggesting that
HPV infection carries an increased risk of developing cer-
vical neoplasia. The same trend was also observed in other
regions or countries. For examples, in Henan, Central
China, the overall HPV prevalence in normal, ASC-US,
LSIL and HSIL cytology samples were 57.1%, 72.5%, 84.0%
and 88.6%, respectively [38]. A population-based study of
HPV genotype prevalence in America showed that the
overall HPV infections were found in 24.3%, 57.9%, 94.6%
and 95.5% of normal, ASC-US, LSIL and HSIL cytology
samples, respectively [13]. The risk of each HPV type for
cervical lesions was estimated using crude ORs. The over-
all OR of HPV infection was 26.1 (95% CI 22.4 to 30.3),
showing that the cervical lesion risk of HPV-infected
women increases to about 26-fold of those uninfected
women. The five most risky HPV types were 73, 16, 82, 45
and 51. HPV 73 had the highest OR for abnormal cytology
(ASC-US, LSIL, ASC-H and HSIL). Although the overall
prevalence of HPV 73 was relatively low (0.2%), HPV 73
infection was at the highest risk of abnormality, which
should be taken more attention to. The association of
HPV 73 and HPV82 with cervical epithelial lesions were
confirmed and the two types were classified as HR type in
previous studies [6,39]. HPV 73 was even more risky than
HPV 16 based on HPV-type-specific risk analysis in Bahia,
Brazil [40] and Northwest Germany [41], which was con-
sistent with our results in this study.
Conclusion
We presented a large cross-sectional study, from which
baseline data of HPV prevalence in Zhejiang Province
was provided. HPV prevalence showed bimodal age dis-
tribution, with a peak at the ≤20 age group and a second
one at >60 age group. HPV 16, 58 and 52 were the most
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http://www.biomedcentral.com/1471-2334/14/708commonly identified HR-HPV types while the vaccine
type HPV 18 showed relatively low prevalence. As ex-
pected, HPV prevalence increased as lesions progressed
to higher grade ones. HPV 73, 16, 82, 45, and 51 were
the most risky types in this area. Our data will provide
guidance for the primary screening and vaccination pro-
gram for cervical cancer.
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